How do I get Renflexis through my insurance?
Renflexis · infliximab-abda · Biosimilar to Remicade · provider-administered IV infliximab
No account, member ID, name, date of birth or email is needed. Your selections stay in this page session.
Make sure the authorization is for Renflexis.
FDA’s Purple Book lists Renflexis (infliximab-abda) as a biosimilar to Remicade under the 351(k) pathway and as a 100 mg single-dose vial for IV use. CMS lists HCPCS Q5104 for Renflexis, with each billing unit representing 10 mg. The treatment site can use Q5104 as a checkpoint when comparing the medicine prescribed, authorized and billed. A billing code does not guarantee coverage.
- Do the prescription and authorization name Renflexis or infliximab-abda?
- Does the current plan rule list Renflexis as preferred, nonpreferred or not addressed?
- Is the infusion site named or restricted in the authorization?
- If a claim failed, do Renflexis, the Q5104 units, service date and site match the approval?
Want to compare the products? Review how Remicade, Inflectra, Avsola and Renflexis can differ in product preference, authorization and billing.
Check the coverage path for Renflexis.
Choose the diagnosis and coverage type. The tool keeps Renflexis selected while you check the plan source and product-preference detail.
Choose the diagnosis / reason.
The same infliximab product family can have very different medical-necessity requirements by diagnosis.
Match the Renflexis approval to the planned infusion.
If Renflexis is preferred
Confirm that the prescriber, authorization team and infusion site all have the Renflexis-specific approval before treatment. An approval that says only “infliximab” may not be specific enough.
If an approved claim fails
Compare the authorization with infliximab-abda, Q5104 units, date, treatment location and provider on the claim before treating it as a new medical-necessity denial.
Find help with your out-of-pocket costs.
Use the official support program below to check savings, patient-assistance, or access options that may apply to you.
Organon Access Program for RENFLEXIS →Questions about Renflexis coverage.
Does an infliximab approval necessarily name Renflexis?
Not necessarily. Ask the plan or authorization department to identify the exact product, code, site and date range approved.
What identifies Renflexis in an authorization or claim?
Look for Renflexis or infliximab-abda. CMS lists Q5104 for Renflexis, with each billing unit representing 10 mg; the treatment site should verify current payer and CMS coding for the claim.
How can I compare Renflexis with other infliximab products?
Compare other infliximab products and coverage considerations, including reference-product, biosimilar, route and common access questions.
The medicine may be only part of the problem.
Use the playbook that matches what is blocking treatment, then verify the current rule with the insurer, program or treatment site.
Approval is pending, expired or unclear.
Find the rule, status and next authorization step.
DENIEDFind the reason before appealing.
Separate medical-necessity, benefit, product and claim problems.
PREFERRED PRODUCTThe plan wants a different brand or biosimilar.
Understand product preference without making a treatment recommendation.
SITE OF CAREThe medicine may be covered, but the location is not.
Check network, site and authorization requirements.
COST TOO HIGHSeparate coverage from financial assistance.
Understand manufacturer support versus independent foundations.
CLAIM PROBLEMAuthorization was approved, but billing still failed.
Compare the approval with the product, site and claim that were billed.
Important
MedicineCostHelp is an educational navigation tool, not an insurer and not a coverage determination. The member’s benefit plan, medical necessity, prior authorization, product preference, current billing code and site-of-care rules can change the outcome. Sources were reviewed 2026-10-08. Verify the current official source before acting.